{"id":"oral-suspension-tedizolid-phosphate","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Optic neuropathy"}]},"_chembl":{"chemblId":"CHEMBL2105669","moleculeType":"Small molecule","molecularWeight":"450.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tedizolid phosphate is rapidly converted to its active form, tedizolid, which binds to the bacterial 50S ribosomal subunit and prevents peptide bond formation, thereby inhibiting protein synthesis. This mechanism is effective against a broad spectrum of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and other resistant pathogens. The oxazolidinone class represents a unique antibiotic mechanism distinct from other protein synthesis inhibitors.","oneSentence":"Tedizolid phosphate is a prodrug that is converted to tedizolid, an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:38.412Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bacterial skin and skin structure infections (ABSSSI)"},{"name":"Community-acquired bacterial pneumonia (CABP)"}]},"trialDetails":[{"nctId":"NCT03176134","phase":"PHASE3","title":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-20","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":100},{"nctId":"NCT03217565","phase":"PHASE1","title":"A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-02-06","conditions":"Gram-Positive Infections","enrollment":47},{"nctId":"NCT06733688","phase":"PHASE1","title":"A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-23","conditions":"Healthy","enrollment":36},{"nctId":"NCT06609161","phase":"PHASE1","title":"A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-16","conditions":"Healthy","enrollment":18},{"nctId":"NCT02750761","phase":"PHASE1","title":"A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-02","conditions":"Gram-Positive Bacterial Infections","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sivextro","TR-701 FA","MK-1986"],"phase":"marketed","status":"active","brandName":"Oral Suspension Tedizolid Phosphate","genericName":"Oral Suspension Tedizolid Phosphate","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tedizolid phosphate is a prodrug that is converted to tedizolid, an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Acute bacterial skin and skin structure infections (ABSSSI), Community-acquired bacterial pneumonia (CABP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}